MA33242B1 - Composes pour le traitement de troubles metaboliques - Google Patents

Composes pour le traitement de troubles metaboliques

Info

Publication number
MA33242B1
MA33242B1 MA34246A MA34246A MA33242B1 MA 33242 B1 MA33242 B1 MA 33242B1 MA 34246 A MA34246 A MA 34246A MA 34246 A MA34246 A MA 34246A MA 33242 B1 MA33242 B1 MA 33242B1
Authority
MA
Morocco
Prior art keywords
metabolic disorders
compounds
treatment
diabetes
exhibit
Prior art date
Application number
MA34246A
Other languages
Arabic (ar)
English (en)
Inventor
Oscar Barba
Matthew Colin Thor Fyfe
Revathy Perpetua Jeevaratnam
Susan Helen Davis
Karen Lesley Schofield
Thomas Staroske
Alan John William Stewart
David Matthew Withall
Simon Andrew Swain
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of MA33242B1 publication Critical patent/MA33242B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés thérapeutiques représentés par la formule (I), qui présentent une activité d'agonistes de GPR119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.
MA34246A 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques MA33242B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904287.0A GB0904287D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050442 WO2010103335A1 (fr) 2009-03-12 2010-03-12 Composés pour le traitement de troubles métaboliques

Publications (1)

Publication Number Publication Date
MA33242B1 true MA33242B1 (fr) 2012-05-02

Family

ID=40600949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34246A MA33242B1 (fr) 2009-03-12 2010-03-12 Composes pour le traitement de troubles metaboliques

Country Status (18)

Country Link
US (1) US20120040953A1 (fr)
EP (1) EP2406256A1 (fr)
JP (1) JP2012520284A (fr)
KR (1) KR20110130476A (fr)
CN (1) CN102395584A (fr)
AU (1) AU2010222673A1 (fr)
BR (1) BRPI1009781A2 (fr)
CA (1) CA2754794A1 (fr)
CL (1) CL2011002221A1 (fr)
EA (1) EA201190209A1 (fr)
GB (1) GB0904287D0 (fr)
IL (1) IL215051A0 (fr)
MA (1) MA33242B1 (fr)
MX (1) MX2011009491A (fr)
PE (1) PE20120356A1 (fr)
SG (1) SG174362A1 (fr)
WO (1) WO2010103335A1 (fr)
ZA (1) ZA201107446B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
GB201114389D0 (en) * 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012066077A1 (fr) * 2010-11-18 2012-05-24 Prosidion Limited Dérivés 1,4 di substitués pyrolidine-3-yl-amine et leur utilisation pour le traitement de troubles métaboliques
CA2836487A1 (fr) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Nouveaux composes utilises comme modulateurs de gpr-119
KR101881932B1 (ko) 2011-12-07 2018-07-27 삼성전자주식회사 자기 소자 및 그 제조 방법
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
MX2022000306A (es) * 2019-07-15 2022-03-11 Oncoarendi Therapeutics Sa Amino triazoles sustituidos utiles como inhibidores de quitinasa.
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
EP1123391A2 (fr) 1998-09-01 2001-08-16 BASF Aktiengesellschaft Methodes permettant d'ameliorer la fonction des recepteurs heterologues couples a la proteine g
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
EP1838706A1 (fr) 2004-12-24 2007-10-03 Prosidion Limited Agonistes du récepteur couplé aux protéines g
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
JP2008545010A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇタンパク質共役受容体アゴニスト
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
CN101379028A (zh) 2006-02-09 2009-03-04 阿斯利康(瑞典)有限公司 化学化合物
NZ571869A (en) 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (fr) 2006-06-21 2007-12-27 Pfizer Products Inc. 3-amino-pyrrolidino-4-lactames substitués
JP5330260B2 (ja) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
WO2008079028A1 (fr) 2006-12-22 2008-07-03 Industrial Research Limited Analogues azétidine d'inhibiteurs de nucléosidase et de phosphorylase
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
WO2009034388A1 (fr) 2007-09-10 2009-03-19 Prosidion Limited Composés pour le traitement de troubles métaboliques
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
KR101136774B1 (ko) 2007-10-18 2012-04-19 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 금속 피복 폴리이미드 복합체 및 그 복합체의 제조 방법 그리고 전자 회로 기판의 제조 방법
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
AU2009269772A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl GPCR agonists
US20110230507A1 (en) 2008-07-10 2011-09-22 Prosidion Limited Piperidine GPCR Agonists

Also Published As

Publication number Publication date
BRPI1009781A2 (pt) 2016-03-08
MX2011009491A (es) 2011-10-11
GB0904287D0 (en) 2009-04-22
ZA201107446B (en) 2012-06-27
US20120040953A1 (en) 2012-02-16
EP2406256A1 (fr) 2012-01-18
EA201190209A1 (ru) 2012-04-30
CN102395584A (zh) 2012-03-28
JP2012520284A (ja) 2012-09-06
IL215051A0 (en) 2011-11-30
SG174362A1 (en) 2011-11-28
WO2010103335A1 (fr) 2010-09-16
KR20110130476A (ko) 2011-12-05
CL2011002221A1 (es) 2012-07-06
PE20120356A1 (es) 2012-04-16
CA2754794A1 (fr) 2010-09-16
AU2010222673A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MA33190B1 (fr) Composes pour le traitement de troubles metaboliques
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA201000046A1 (ru) Замещенные имидазогетероциклы
MA34235B1 (fr) Composes chimiques
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
TW200612911A (en) Compounds for the treatment of inflammatory disorders
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
TW200612926A (en) Compounds and compositions as ppar modulators
TW200738688A (en) Compounds for the treatment of inflammatory disorders
MA33428B1 (fr) Agonistes du gpr119
EA200701471A1 (ru) Замещённые пиридинильные и пиримидинильные производные, используемые в качестве модуляторов метаболизма и лечение ассоциированных с ним расстройств
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
JO2686B1 (en) Vehicles
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119